Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
brief summary
The purpose of this trial is to learn whether participants who take rilogrotug gain weight, have a better appetite, and have a better quality of life than participants who do not take rilogrotug (placebo arm). Adult participants with cachexia who have also been diagnosed with metastatic colorectal or non-small cell lung cancer will be enrolled. The primary hypothesis is that after 12 weeks, rilogrotug will cause an increase from baseline in body weight and appetite (as measured by the Functional Assessment of Anorexia/Cachexia Therapy 5-item Anorexia Symptom Scale \[FAACT-5IASS\] questionnaire) compared to placebo.
detailed description
This multicenter, randomized, double-blind, placebo-controlled Phase 2/3 study is designed to compare the efficacy and safety of rilogrotug to a control arm of placebo for treatment of weight loss and anorexia in participants with cachexia who have also been diagnosed with metastatic colorectal cancer (mCRC) or metastatic non-small cell lung cancer (mNSCLC) and are receiving first line anticancer standard of care. The master protocol is designed with 4 sub-studies:
The Phase 2 (A) sub-study is designed to compare the efficacy and safety of two dose levels of rilogrotug (Arm 1 or Arm 2) to a control arm of placebo (Arm 3) in a 1:1:1 allocation. It is anticipated that the sub-study will enroll approximately 150 participants across 3 arms.
The Phase 3 (B) sub-study is designed to assess safety and efficacy of the selected optimal dose versus placebo in patients with cancer cachexia and mCRC in a 1:1 allocation. It is anticipated that the sub-study will enroll approximately 400 participants across 2 arms.
The Phase 3 (C) sub-study is designed to assess safety and efficacy of the selected optimal dose versus placebo in patients with cancer cachexia and mNSCLC in a 1:1 allocation. It is anticipated that the sub-study will enroll approximately 400 participants across 2 arms.
The OLE (D) sub-study is designed to allow participants who have completed one of the parent sub-studies (A), (B), (C) to continue receiving rilogrotug for up to an additional 12 months.
official title
A Phase 2/3 Randomized, Double-Blind Study of Rilogrotug Versus Placebo in the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC